Essential HTN. Reduction of the risk of MI, stroke or death in patients ≥55 yr at high risk developing major CV events who are unable to take ACE inhibitors. High risk CV events including evidence of CAD, peripheral arterial disease, stroke, transient ischemic attack or diabetes w/ evidence of end-organ damage. Additional treatment to antihypertensive, antiplatelet or lipid-lowering therapy.
Dosage/Direction for Use
Adult Essential HTN 40 mg once daily, may be increased to max: 80 mg once daily. Severe HTN 160 mg alone &/or in combination w/ hydrochlorothiazide 12.5-25 mg daily. CV risk reduction 80 mg once daily. Mild to moderate hepatic impairment Not to exceed 40 mg once daily.
*The product images shown are for illustration purposes only and may not be an exact representation of the product.